Naltrexone Implant for Alcohol Use Disorder: What Does the Evidence Actually Show?
Naltrexone is an established medication for alcohol use disorder, but the evidence is not identical for every way the medication is delivered. Oral naltrexone and extended-release injectable naltrexone have substantial clinical evidence and are FDA-approved options in the United States. Sustained-release naltrexone implants use the same opioid-antagonist drug but a different delivery system, and implant-specific evidence remains smaller and more formulation-dependent.
A long-acting implant may reduce repeated medication-adherence decisions, but it should not be presented as a treatment that eliminates the desire to drink, guarantees abstinence or replaces counselling. It is also essential to separate treatment of acute alcohol withdrawal from medication used for the longer-term management of alcohol use disorder.
Naltrexone implant formulations are not FDA-approved for clinical use in the United States. FDA-approved U.S. medications for alcohol use disorder include oral naltrexone, extended-release injectable naltrexone, acamprosate and disulfiram. DeBinge implant-based treatment takes place in Nassau, The Bahamas, following individual medical assessment.
Does Naltrexone Work for Alcohol Use Disorder?
Yes, naltrexone has a well-established evidence base for alcohol use disorder. Large systematic reviews support oral naltrexone for reducing the risk of returning to heavy drinking in appropriately selected patients. Extended-release injectable naltrexone also has randomized clinical-trial evidence showing modest reductions in drinking outcomes.
The important qualification is that evidence for oral tablets or monthly Vivitrol® injections cannot automatically be treated as evidence for every naltrexone implant. Implant formulations may differ in dose, release technology, duration and pharmacokinetics. Implant-specific alcohol research exists and newer research is emerging, but the overall evidence base is substantially smaller than the evidence for established oral naltrexone.
For a broader explanation of the medication, pharmacology, safety and implant evidence, read our long-acting naltrexone implant guide.
What Is Alcohol Use Disorder?
Alcohol use disorder, usually shortened to AUD, is a medical condition characterized by a problematic pattern of alcohol use that causes clinically significant impairment or distress. Under DSM-5-TR criteria, AUD is classified as mild, moderate or severe according to how many diagnostic symptoms are present during a 12-month period.
AUD can involve difficulty controlling alcohol use, drinking more or for longer than intended, unsuccessful attempts to cut down, strong urges to drink, continued drinking despite harm, tolerance and withdrawal. Not everyone with AUD has the same pattern or severity, so treatment needs to be individualized.
The National Institute on Alcohol Abuse and Alcoholism describes evidence-based care as potentially including behavioural healthcare, medications and mutual-support approaches. Treatment may take place in primary care, specialist outpatient settings, intensive outpatient programs, residential services or inpatient care depending on the individual’s needs.
Alcohol Withdrawal and Long-Term AUD Treatment Are Not the Same Thing
This distinction is one of the most important safety issues when discussing naltrexone.
Naltrexone does not treat acute alcohol withdrawal. It is a medication used as part of longer-term treatment for alcohol use disorder. It should not be presented as a substitute for appropriate withdrawal management in someone who is physically dependent on alcohol.
When a person has been drinking heavily and regularly, suddenly stopping alcohol can produce withdrawal. Symptoms can include tremor, sweating, anxiety, insomnia, nausea, vomiting, elevated heart rate and blood pressure. More severe withdrawal can involve seizures, hallucinations or delirium tremens.
NIAAA states that alcohol withdrawal can be life-threatening in some patients and that people at risk may require medically managed withdrawal. Benzodiazepines remain a principal evidence-based treatment for acute alcohol withdrawal, with treatment setting and monitoring determined by severity and individual risk.
If someone drinks heavily every day, has previously experienced withdrawal, has had withdrawal seizures or delirium, or becomes unwell when alcohol wears off, stopping suddenly without medical assessment can be dangerous.
Detoxification can be an important first step, but NIAAA emphasizes that detox alone is not alcohol treatment. Long-term management addresses the factors that contribute to continued alcohol use and the risk of returning to harmful drinking.
How Does Naltrexone Work for Alcohol Dependence?
Naltrexone is an opioid receptor antagonist, with clinically important activity at mu-opioid receptors. That mechanism is easy to understand in opioid treatment because opioids directly activate opioid receptors. Alcohol is different: alcohol does not simply bind to the opioid receptor in the way heroin or morphine does.
Instead, the body’s endogenous opioid system participates in reward and reinforcement pathways involved in drinking. By blocking opioid receptors, naltrexone can reduce some of alcohol’s rewarding or reinforcing effects. For some people this can reduce the urge to continue drinking after alcohol use begins or make heavy drinking less reinforcing.
This does not mean that naltrexone makes alcohol biologically inactive. Someone can still become intoxicated, experience impaired coordination and judgment, sustain alcohol-related organ damage or experience an alcohol overdose while taking naltrexone.
It is also inaccurate to say that naltrexone eliminates the desire for alcohol. Clinical response is variable. Some people experience a meaningful reduction in craving or heavy drinking; others obtain limited benefit. Behaviour, environment, stress, learned associations and social circumstances continue to matter.
What Medications Are FDA-Approved for Alcohol Use Disorder in the U.S.?
NIAAA identifies three medication categories approved by the U.S. Food and Drug Administration for AUD: naltrexone, acamprosate and disulfiram. Naltrexone is available in FDA-approved oral and extended-release injectable formulations.
| Medication | Basic role | Important practical consideration |
|---|---|---|
| Oral naltrexone | Opioid antagonist used to reduce alcohol reinforcement and the risk of heavy drinking. | Requires ongoing tablet adherence and cannot be used safely in someone with current opioid dependence. |
| Extended-release injectable naltrexone | Monthly intramuscular naltrexone formulation, commonly known by the U.S. brand Vivitrol®. | Reduces daily adherence demands but requires repeated injections and consideration of injection-related risks. |
| Acamprosate | Used primarily to help maintain abstinence after alcohol cessation. | Requires multiple daily doses, and kidney function is an important prescribing consideration. |
| Disulfiram | Interferes with alcohol metabolism, producing an unpleasant reaction when alcohol is consumed. | Works through a fundamentally different mechanism and requires careful patient selection and adherence. |
Medication selection is not simply a contest between products. Goals, previous response, liver and kidney health, current opioid use, adherence, pregnancy considerations, other medications and patient preference can all affect the decision.
For a detailed formulation comparison, see compare oral naltrexone, Vivitrol and implants.
What Does the Evidence Show for Oral Naltrexone?
Oral naltrexone has one of the stronger medication evidence bases in alcohol use disorder.
2023 JAMA systematic review and meta-analysis
A major systematic review published in JAMA in 2023 evaluated 118 clinical trials involving 20,976 participants. It found moderate-strength evidence supporting oral naltrexone at 50 mg per day for several drinking outcomes.
The authors calculated that approximately 18 people would need to be treated with oral naltrexone to prevent one additional return to any drinking compared with placebo, and approximately 11 would need treatment to prevent one additional return to heavy drinking. The review concluded that oral naltrexone and acamprosate should be considered first-line pharmacotherapies for AUD alongside psychosocial interventions.
These averages describe groups, not individual outcomes. They do not mean that every patient will respond or that someone who responds will stop drinking completely.
Oral naltrexone also exposes a practical problem that helped motivate development of longer-acting formulations: medication only works when the person continues to take it. A person who forgets doses, loses motivation or intentionally stops medication before drinking may lose the intended pharmacological support.
What Does the Evidence Show for Vivitrol and Other Extended-Release Injectable Naltrexone?
Extended-release injectable naltrexone provides sustained medication exposure for approximately one month after an intramuscular injection. Vivitrol is FDA-approved in the United States for alcohol dependence in appropriately selected patients and is also approved for prevention of relapse to opioid dependence following detoxification.
Current U.S. prescribing information states that Vivitrol treatment for alcohol dependence should be part of a comprehensive management program including psychosocial support. For its alcohol indication, patients should be able to abstain from alcohol before initial administration and should not be actively drinking at the time of the first injection.
2021 systematic review of injectable extended-release naltrexone
A systematic review and meta-analysis of seven randomized placebo-controlled trials involving 1,500 adults with AUD found that monthly extended-release naltrexone was associated, on average, with approximately two fewer drinking days and around one fewer heavy-drinking day per month compared with placebo. Participants also received behavioural therapy in the included trials.
The effect was therefore clinically relevant but not equivalent to guaranteed abstinence.
A 2025 randomized clinical trial in hospitalized patients with AUD directly compared oral naltrexone with extended-release injectable naltrexone. Heavy drinking decreased substantially in both groups, but the difference between the formulations was not statistically significant at three months. That finding reinforces the importance of access, adherence, preference and cost rather than assuming the injectable form must always produce a better clinical outcome.
What Is a Sustained-Release Naltrexone Implant?
A naltrexone implant places a sustained-release formulation beneath the skin so that the medication is released gradually over an extended period. The underlying adherence rationale is similar to the monthly injection: reduce the number of times a patient needs to decide whether to take medication.
An implant may extend this principle over a longer period depending on the formulation. However, there is no single universal “naltrexone implant.” Different products have been developed with different drug doses, polymers, release profiles and intended durations.
A study of one implant does not prove that a different implant has the same duration, blood concentrations, safety profile or treatment effect.
The implant also introduces considerations that tablets do not: placement is a medical procedure and can involve local pain, bruising, infection, scarring, wound problems or other implant-site complications. These risks need to be considered alongside medication-related risks.
Naltrexone implant formulations are not FDA-approved for clinical use in the United States. FDA approval of oral naltrexone or Vivitrol should not be presented as FDA approval of an implant.
What Does Naltrexone Implant Research for Alcohol Use Disorder Actually Establish?
The clearest answer is: there is a scientific rationale and some implant-specific clinical evidence, but the evidence remains much smaller than the evidence for oral naltrexone and should not be generalized across all products.
Earlier depot and implant literature
A systematic review of depot naltrexone formulations published in 2011 evaluated both injectable and implant technologies for opioid and alcohol dependence. It recognized adherence as a major rationale for sustained-release treatment, but noted that the alcohol evidence at that time was driven largely by depot injection studies rather than robust implant trials. The review also emphasized that larger longitudinal studies of implants were needed.
Read the depot and implant systematic review
Observational implant research
An Australian observational study published in 2014 examined healthcare use among 94 people who received implant naltrexone for problematic alcohol use. Hospital events and associated healthcare costs were lower in the six months after treatment than in the six months before treatment.
This is potentially useful real-world information, but a before-and-after observational study cannot prove that the implant caused the improvement. Other treatment, counselling, motivation, regression to the mean and changes occurring around entry into care may contribute.
View the observational implant study on PubMed
Emerging randomized implant evidence
More recent evidence is beginning to address this gap. A 2026 publication in Addiction Biology reported data from a randomized, double-blind, placebo-controlled study involving 70 participants with AUD who received naltrexone implants or placebo. The prespecified primary outcome, percentage of heavy-drinking days across 24 weeks, favoured the naltrexone group.
This is important because it represents implant-specific randomized evidence in AUD rather than borrowing evidence from oral tablets or Vivitrol. It is also important not to overinterpret it. Seventy participants is a relatively small evidence base, the report focused substantially on mechanistic biomarker research, and one study does not establish that every implant formulation will produce the same result.
View the 2026 randomized implant research on PubMed
Naltrexone itself is an evidence-based medication for AUD. Sustained-release delivery can address medication-adherence problems. Implant-specific AUD evidence is emerging and includes randomized data, but it remains limited compared with established oral naltrexone evidence and cannot be assumed to apply equally to every implant product.
What Should Be Assessed Before Naltrexone Treatment for Alcohol Use Disorder?
Naltrexone may be appropriate for many people with AUD, but medication choice requires individual assessment.
Current opioid use
This can be overlooked when alcohol is the main problem. Naltrexone blocks opioid receptors and can precipitate severe withdrawal if given to someone who is physically dependent on opioids.
Patients should disclose prescription opioid pain medications, methadone, buprenorphine, tramadol and non-prescribed opioid exposure before naltrexone treatment.
Liver health
Because AUD can coexist with alcohol-related liver disease and naltrexone has hepatic safety considerations, clinicians may need to assess liver history, symptoms and laboratory results depending on the patient’s circumstances.
Kidney health
Renal function is especially relevant when considering alternatives such as acamprosate, which is cleared through the kidneys and is not appropriate in severe renal impairment.
Future pain treatment
Long-acting naltrexone can complicate the use of opioid analgesics. Planned surgery, chronic pain treatment or other likely opioid requirements should be discussed before choosing a long-duration antagonist formulation.
Any clinic offering long-acting treatment should ask about more than drinking frequency. Medication lists, prior treatment, withdrawal history, medical conditions and treatment goals all matter.
Why Long-Acting Naltrexone May Be Considered When Adherence Is Difficult
Adherence is one of the strongest practical arguments for sustained-release treatment.
A person taking oral naltrexone usually needs to continue making a medication decision repeatedly. During a stressful period or when the intention to drink becomes stronger, deliberately stopping the tablet can undermine treatment.
A monthly injection reduces those daily decisions. An implant can theoretically extend the same adherence advantage over a longer period if the particular formulation maintains clinically relevant naltrexone exposure.
But medication adherence is not the same thing as recovery adherence. A long-acting formulation cannot make someone attend counselling, change a high-risk social environment, improve sleep, resolve relationship conflict, process trauma or develop new coping strategies.
Long-acting medication is best understood as one potential component of a broader plan rather than an alternative to that plan.
Why Counselling Still Matters
NIAAA describes several evidence-based behavioural approaches for AUD, including cognitive behavioural therapy, motivational enhancement approaches, mindfulness-based treatments, contingency management, couples or family therapy and 12-step facilitation.
The role of counselling is not to duplicate what medication does. Medication may modify biological reinforcement and craving. Behavioural treatment works on different parts of the problem.
That can include:
- identifying high-risk drinking situations;
- understanding triggers and learned drinking patterns;
- developing alternatives to alcohol for stress regulation;
- planning for social situations involving alcohol;
- improving sleep, routine and daily structure;
- addressing relationship or family patterns;
- treating co-occurring psychiatric problems where appropriate;
- recognizing early warning signs of return to harmful drinking;
- developing a response plan before a lapse becomes a prolonged return to heavy use.
FDA prescribing information for Vivitrol specifically states that medication should be part of a comprehensive management program that includes psychosocial support. The same principle is sensible when considering any longer-acting naltrexone formulation.
Medication Is Not the Same as Relapse-Prevention Planning
A person can respond well to naltrexone and still encounter situations that threaten recovery. Medication may change the reinforcing effects of alcohol, but it does not remove alcohol from restaurants, homes, social circles, workplaces or stressful situations.
A useful relapse-prevention plan asks practical questions:
- What situations usually lead to drinking?
- What happens after the first drink?
- Who knows about the treatment plan and can provide support?
- What should happen if drinking begins again?
- Which clinician should be contacted?
- What psychological or social issues still need treatment?
- How will progress be measured?
- What happens when long-acting medication eventually wears off?
See our guide to continuing relapse-prevention planning.
Are Naltrexone Implants FDA-Approved for Alcohol Use Disorder?
FDA approval applies to a specific medication formulation and indication, not simply to the active drug molecule.
In the United States, naltrexone is FDA-approved in oral form for alcohol dependence, and extended-release injectable naltrexone is FDA-approved for alcohol dependence under its prescribing conditions. Acamprosate and disulfiram are also FDA-approved for AUD.
A sustained-release subcutaneous implant containing naltrexone is a different drug-delivery system. It therefore cannot be advertised responsibly as FDA-approved simply because naltrexone itself is an FDA-approved molecule.
Patients should ask implant providers:
- what exact implant formulation is being proposed;
- what dose and release technology it uses;
- what studies investigated that formulation;
- where it is manufactured;
- what regulatory framework applies where treatment is performed;
- what procedure-related complications have been documented;
- what follow-up is available if a problem occurs.
For more detail about geography and regulation, read treatment availability in the U.S. and The Bahamas.
Where DeBinge Fits
DeBinge provides implant-based treatment in Nassau, The Bahamas. DeBinge does not provide naltrexone implant procedures in the United States.
For someone considering treatment for alcohol use disorder, the process should begin with medical assessment rather than an assumption that an implant is automatically the best option.
The clinical discussion needs to consider current drinking, previous withdrawal, medical history, liver and kidney considerations, opioid medications or opioid use, previous AUD medications, treatment goals, counselling needs and whether international treatment is appropriate.
Someone at risk of dangerous alcohol withdrawal may need withdrawal management before longer-term medication planning. Travelling should only occur when it is medically appropriate to do so.
Patients who value discretion can also read about private treatment planning.
Considering medication after alcohol detox?
The useful question is not simply “Which treatment lasts longest?” It is which medication, formulation, behavioural treatment and follow-up plan best fit the individual clinical situation.
Understand Long-Acting Naltrexone Compare Naltrexone FormulationsWhat Should You Discuss With a Clinician About Medication After Alcohol Detox?
This nine-question tool does not diagnose alcohol use disorder, recommend a medication or determine whether an implant is suitable. It identifies areas that may need more discussion with a qualified clinician.
Your answers are processed only inside your browser and are not submitted to DeBinge.
Topics Worth Discussing in More Detail
Your responses highlight areas that may deserve attention before choosing medication. They do not tell you which treatment to use.
Naltrexone Implant and Alcohol Use Disorder FAQ
Does naltrexone treat alcohol withdrawal?
No. Naltrexone is used for longer-term treatment of alcohol use disorder; it is not a treatment for acute alcohol withdrawal. Withdrawal can be dangerous and may require medical management, particularly in people with a history of heavy sustained drinking, seizures or delirium tremens.
Does naltrexone make someone unable to drink?
No. Unlike disulfiram, naltrexone does not intentionally create an aversive alcohol reaction. A person can still drink while naltrexone is active. The intended effect is to modify reward and reinforcement pathways and, for some patients, reduce heavy drinking or craving.
Does naltrexone eliminate alcohol cravings?
No. Naltrexone may reduce craving for some people, but response varies and psychological or environmental triggers can remain. It should not be presented as eliminating desire for alcohol.
Is Vivitrol the same as a naltrexone implant?
No. Vivitrol is an FDA-approved extended-release intramuscular naltrexone injection generally administered once every four weeks. An implant is placed beneath the skin and uses a different sustained-release delivery system.
Are naltrexone implants FDA-approved for alcohol use disorder?
No naltrexone implant formulation is FDA-approved for clinical use in the United States. FDA-approved AUD medications include oral naltrexone, extended-release injectable naltrexone, acamprosate and disulfiram.
Is there evidence that implants can help with AUD?
There is some implant-specific evidence, including observational research and newer randomized research. However, the evidence base is smaller than for oral naltrexone, and results from one implant formulation should not automatically be applied to another.
Why consider a long-acting formulation?
The main rationale is adherence. A long-acting formulation can reduce the number of medication decisions required compared with taking tablets regularly. Whether that advantage justifies an injection or implant depends on the individual’s circumstances.
Can someone taking opioid pain medication use naltrexone for alcohol problems?
Naltrexone blocks opioid receptors and can interfere with opioid analgesia. It can also precipitate severe withdrawal in someone physically dependent on opioids. All prescription and non-prescription opioid exposure should be discussed with a clinician before treatment.
What about liver problems?
AUD frequently coexists with liver disease, and naltrexone has liver-related prescribing considerations. Liver history, symptoms and relevant laboratory results should be reviewed by a clinician rather than assuming naltrexone is automatically appropriate or inappropriate.
Is acamprosate an alternative to naltrexone?
Yes. Acamprosate is another FDA-approved AUD medication and has strong evidence, particularly for supporting abstinence. It works differently from naltrexone and has important renal prescribing considerations.
Does medication replace counselling?
No. Medication and behavioural treatment address different parts of AUD. Evidence-based care commonly combines medication with counselling, medical follow-up, mutual support or other recovery resources according to individual needs.
Where does DeBinge provide implant-based treatment?
DeBinge implant-based treatment takes place in Nassau, The Bahamas. Suitability requires medical assessment, and international travel should only be planned when clinically appropriate.
Clinical and Scientific Sources
NIAAA: Alcohol Use Disorder
National Institute on Alcohol Abuse and Alcoholism guidance on AUD diagnosis, withdrawal, behavioural care and medication treatment.
NIAAA: AUD Medications
NIAAA information on naltrexone, acamprosate and disulfiram as FDA-approved medications for AUD.
SAMHSA: Naltrexone
SAMHSA information on oral and extended-release naltrexone and the role of counselling and behavioural therapies in treatment.
Vivitrol Prescribing Information
Current U.S. prescribing information covering the alcohol-dependence indication, psychosocial support, opioid-related precautions and other safety information.
JAMA 2023 AUD Medication Review
McPheeters M, et al. Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis. JAMA. 2023;330(17):1653-1665.
Injectable Naltrexone Meta-Analysis
Murphy CE, et al. Systematic review and meta-analysis of extended-release injectable naltrexone for alcohol consumption outcomes.
Depot and Implant Systematic Review
Lobmaier PP, et al. Naltrexone depot formulations for opioid and alcohol dependence: a systematic review.
2026 Implant Research
A randomized double-blind placebo-controlled implant study in 70 participants with AUD was reported in a 2026 Addiction Biology publication. It provides emerging implant-specific evidence but should not be generalized to every implant formulation.
Evidence and regulatory information reviewed for this page in September 2026. Clinical guidance, labeling and regulatory status can change. Patients should confirm current prescribing information and discuss individual circumstances with a qualified clinician.
Prepared for Medical Review by Dr Fergus Law, BSc, MBChB, FRCPsych
Consultant Psychiatrist specialising in substance misuse and addiction psychiatry.
This page has been prepared as an evidence-based educational resource and is awaiting formal clinical approval. Until that review is completed, it should not be represented as having been medically reviewed.
View Dr Fergus Law’s professional profile
Review status: Pending clinical approvalEducational Information, Not Individual Medical Advice
This page is intended to explain evidence relating to naltrexone and alcohol use disorder. It cannot determine whether oral naltrexone, injectable naltrexone, an implant, acamprosate, disulfiram or another treatment is appropriate for a particular person.
Do not abruptly stop heavy regular alcohol use, begin detoxification, alter prescribed medication or start naltrexone based solely on this article. Alcohol withdrawal can be medically dangerous and requires individual risk assessment.
Seizures, severe confusion, hallucinations, inability to remain conscious, abnormal breathing, suspected alcohol poisoning or other serious symptoms require urgent local medical assistance.